Navigation Links
MIABE standard opens up new opportunities in drug discovery
Date:9/1/2011

AUDIO: This audio file is a brief interview with MIABE coauthors Sandra Orchard, John Overington, Dominic Clark and Christoph Steinbeck of the EMBL-European Bioinformatics Institute. They briefly discuss the potential impact...

Click here for more information.

An international consortium of pharmaceutical companies, public and commercial data providers and academic groups has agreed on a new standard for describing the effect of a compound on a biological entity. Published in Nature Reviews Drug Discovery, the Minimum Information about a Bioactive Entity (MIABE) standard makes it possible to enhance the interchange of public data on drug discovery success and attrition.

Every day, pharma, biotech and academic groups generate enormous quantities of data about the biological properties of molecules such as drugs, pesticides and food additives. However, not all useful data are reported. This can lead to fruitless repetition of work, wasting time, energy and resources.

A deeper understanding of what makes successful drugs work can be gained by putting together data from a large number of drug discovery programmes. But to analyse these data properly, they need to be comparable. At present, crucial data are often missing from the published literature or are reported in an unstructured format.

MIABE reporting guidelines will allow the scientific community to capture more information about bioactive compounds, and to use that information for better design.

"We hope that MIABE will make possible an order-of-magnitude increase in the amount of data available for analysis," explained Dr John Overington, who heads the ChEMBL group at the European Molecular Biology Laboratory's European Bioinformatics Institute (EMBL-EBI). "Experience with other standards has shown that as more groups come to adopt them, the amount of useable data available to researchers snowballs."

"The increased availability of standards-compliant data will help companies to streamline their decision-making processes," said Dr Dominic Clark, who coordinates the Industry Programme at EMBL-EBI. "Industry is becoming increasingly reliant on data in the public domain. Having a set of principles and standards will make data integration simpler and help to control costs."

"This new standard will bring us a wealth of well curated data about the biological targets of bioactive molecules a very timely initiative for the EMBL-EBI's current expansion in the area of metabolism and metabolomics," added Dr Christoph Steinbeck, who heads the cheminformatics team at EMBL-EBI.

MIABE is the result of a precompetitive project that originated in the EMBL-EBI Industry Programme. The ideas were originally developed in a series of drug-discovery research workshops, and the outcome will benefit industrial and academic communities alike.


'/>"/>

Contact: Mary Bergman
mary@ebi.ac.uk
44-122-349-4665
European Molecular Biology Laboratory
Source:Eurekalert

Related biology technology :

1. Randomized Study Comparing Cell Therapeutics OPAXIO (Paclitaxel Poliglumex) and Radiotherapy to Standard of Care Temozolomide and Radiotherapy Treatment Open for Enrollment
2. International Isotopes Inc. Announces Successful International Standards Certification for Manufacture of Its Nuclear Medicine Products and Devices
3. SGS Certified for ISTA Standard 20 Insulated Shipping Container Testing
4. Transgenomic Announces Discovery of a Novel Technique Which Enhances Analytic Sensitivity of Standard Sanger Sequencing to 1%
5. RadQual, LLC Announces a New Industry Leading Dose Calibrator Reference Standard
6. Dynamic Ventures Corporations Information To Be Available Through Standard & Poors Market Access Program
7. IGEN Networks Corp. obtains Blue Sky Statutory Compliance in 38 States with Approval of Standard & Poors
8. CRAiLAR® Organic Fibers is Approved for Global Organic Textile Standard Chemical Input Certification
9. OriGene Technologies Launches Over 5,000 Heavy Isotope Labeled Full-Length Human Proteins as Quantitative Internal Standards for SRM/MRM Mass Spectrometry
10. US Oncology Continues to Set the Standard as a VAWD(CM) Accredited Wholesale Distributor
11. InterTech Service to Counter Widely Reported Problems in Automotive, Medical Device and Other Industries Requiring Rigorous Quality Standards
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/3/2016)...  With the growing need for better therapeutics, ... therapies such as monoclonal antibodies, recombinant protein therapeutics ... indications are in high demand. Conventionally expression systems ... production of these therapeutics. However, due to issues ... novel approaches and novel expression systems are currently ...
(Date:2/3/2016)... Mass., Feb. 3, 2016 Harvard Apparatus ... biotechnology company developing bioengineered organ implants for life-threatening ... announced that CEO Jim McGorry , will ... Conference on Tuesday, February 9, 2016 at ... City . HART,s presentation will be webcast ...
(Date:2/3/2016)... ... February 03, 2016 , ... ... a new office dedicated to the North American healthcare market. , Aerocom Healthcare, ... healthcare facilities. The company will provide new pneumatic tube systems or expand ...
(Date:2/3/2016)... CA (PRWEB) , ... February 03, 2016 , ... ... of remote Linux and Unix visualization solutions today announced the addition of a ... Preview allows users to see the current state of the remote Linux desktop ...
Breaking Biology Technology:
(Date:1/11/2016)... 2016  higi, the leading retail and omni-channel community ... web and mobile, today announced it has closed ... investors. --> --> ... innovate higi,s health platform – its network of ... including expanding services and programs to retail partners ...
(Date:1/8/2016)... OXFORD, Connecticut , January 8, 2016 ... growing m-commerce market and WorldVentures ® , a privately ... memberships and an Inc. 5000 fastest-growing company ... a strategic investment of $2 million in Nxt-ID to ... members based on Nxt-ID,s Wocket ® , a unique ...
(Date:1/7/2016)... , Jan. 7, 2016 Various factors ... biopharmaceutical products such as biologics and biosimilars. Some ... reduce healthcare expenditure, growing demand for cost-effective alternatives, ... population. Biosimilars are similar versions of their corresponding ... to their quality, safety, and efficacy. The global ...
Breaking Biology News(10 mins):